<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297452</url>
  </required_header>
  <id_info>
    <org_study_id>10-192</org_study_id>
    <nct_id>NCT01297452</nct_id>
  </id_info>
  <brief_title>BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sai Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the good and bad effects that occur when BKM120 is&#xD;
      added to standard chemotherapy with carboplatin and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2011</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the phase II recommended dose of daily oral BKM120</measure>
    <time_frame>2 years</time_frame>
    <description>for patients with advanced solid tumors, BKM120 in combination with two different schedules of paclitaxel and carboplatin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EXPANSION COHORT A:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim support</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EXPANSION COHORT B: To obtain a preliminary description of efficacy of the regimen established in Group 1 among patients with tumors harboring PTEN mutation or homozygous deletion.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the safety of BKM120 combined with paclitaxel and carboplatin,</measure>
    <time_frame>weekly clinic visits during Cycle 1, on Day 1 of subsequent cycles,</time_frame>
    <description>Patients will be evaluated by MD at weekly clinic visits during Cycle 1, on Day 1 of subsequent cycles, and will have additional evaluations if clinically indicated. Toxicities will be assessed according to NCI common toxicity criteria (CTC) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic profile of daily BKM120.</measure>
    <time_frame>2 years</time_frame>
    <description>when given in combination with carboplatin and paclitaxel. The area under the curve (AUC0→∞), half-life (t½), and maximum concentration (Cmax) for BKM120 will be determined by noncompartmental analysis.(except for Expansion Cohort B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe and tabulate the radiographic response rate of BKM120 in combination with carboplatin and paclitaxel,</measure>
    <time_frame>2 years</time_frame>
    <description>there is insufficient sample size to support a formal analysis of response rate. As such, radiographic response data will be tabulated and presented in descriptive form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Tissue Studies</measure>
    <time_frame>2 years</time_frame>
    <description>we will calculate the proportion of cases with positive staining of PTEN along with a 95% confidence interval, using the Clopper and Pearson method for exact small sample inference. For Sequenom Analysis, we will calculate the proportion of cases that are positive for each mutation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BKM120 (days 1 - 21) + paclitaxel + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BKM120 (days 1 - 28, ) + paclitaxel + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 days 1 - 21 plus paclitaxel + carboplatin</intervention_name>
    <description>Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.</description>
    <arm_group_label>BKM120 (days 1 - 21) + paclitaxel + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin</intervention_name>
    <description>Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.</description>
    <arm_group_label>BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B</arm_group_label>
    <arm_group_label>BKM120 (days 1 - 28, ) + paclitaxel + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)</intervention_name>
    <description>BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A</description>
    <arm_group_label>BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120, Paclitaxel + Carboplatin</intervention_name>
    <description>BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B</description>
    <arm_group_label>BKM120 (days 1 - 21) + paclitaxel + carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed recurrent or metastatic advanced solid tumor, for which there&#xD;
             is no curative-intent treatment option. Pathology confirmation must be performed at&#xD;
             MSKCC.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L,&#xD;
             Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Total calcium (corrected for serum albumin) within normal limits (biphosphonate use&#xD;
             for malignant hypercalcemia control is not allowed)&#xD;
&#xD;
          -  Magnesium ≥ the lower limit of normal&#xD;
&#xD;
          -  Adequate liver function.&#xD;
&#xD;
          -  Serum bilirubin must be within the upper limit of normal. (ULN). AST and ALT and&#xD;
             Alkaline Phosphatase must be within the range allowing for eligibility. In determining&#xD;
             eligibility the more abnormal of the two values (AST or ALT) should be used.&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 55 mL/min&#xD;
&#xD;
          -  Fasting plasma glucose (FPG) ≤120 mg/dL or ≤6.7 mmol/L&#xD;
&#xD;
          -  HbA1c ≤ 8%&#xD;
&#xD;
          -  Negative serum pregnancy test within 14 days before starting study treatment in women&#xD;
             with childbearing potential&#xD;
&#xD;
          -  Ability to swallow oral medication&#xD;
&#xD;
          -  EXPANSION COHORT B ONLY: Documented genetic alteration (mutation or homozygous&#xD;
             deletion) in the PTEN gene, identified by the MSKCC IMPACT assay platform or other&#xD;
             CLIA-approved test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received prior treatment with a P13K inhibitor.&#xD;
&#xD;
          -  Patients with a known hypersensitivity to BKM120 or to its excipients&#xD;
&#xD;
          -  Patients with untreated brain metastases are excluded. However, patients with&#xD;
             metastatic CNS tumors may participate in this trial, if the patient is &gt; 4 weeks from&#xD;
             therapy completion (incl. radiation and/or surgery), is clinically stable at the time&#xD;
             of study entry and is not receiving corticosteroid therapy&#xD;
&#xD;
          -  Patients with acute or chronic liver, renal disease or pancreatitis&#xD;
&#xD;
          -  Patients with the following mood disorders as judged by the Investigator or a&#xD;
             psychiatrist, or as result of patient's mood assessment questionnaire:&#xD;
&#xD;
               -  medically documented history of or active major depressive episode, bipolar&#xD;
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of&#xD;
                  suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm&#xD;
                  to others)&#xD;
&#xD;
                  *≥ CTCAE grade 3 anxiety&#xD;
&#xD;
               -  At screening, mood rating scores of ≥ 10 on PHQ-9 and/or ≥ 15 on GAD-7, unless&#xD;
                  overruled by psychiatrist's assessment&#xD;
&#xD;
          -  Patient selects a response of &quot;1, 2, or 3&quot; for question 9 on PHQ-9 questionnaire&#xD;
             regarding potential for suicidal thoughts or ideation (independent of the total score&#xD;
             of the PHQ-9) Note: The psychiatric judgment overrules the mood assessment&#xD;
             questionnaire result/investigators judgment. If mood rating scores do not meet&#xD;
             eligibility criteria and/or the investigator deems that a patient has mood disorder&#xD;
             that renders the patient ineligible, that patient may not be registered to the study&#xD;
             unless there is a subsequent psychiatric clinic consultation in which the psychiatrist&#xD;
             overrules the mood assessment questionnaire result/investigator judgment.&#xD;
&#xD;
          -  Patients with diarrhea ≥ CTCAE grade 2&#xD;
&#xD;
          -  Any of the following concurrent severe and/or uncontrolled medical conditions which&#xD;
             could compromise participation in the study:&#xD;
&#xD;
          -  ST depression or elevation of ≥ 1.5 mm in 2 or more leads&#xD;
&#xD;
          -  Congenital long QT syndrome&#xD;
&#xD;
          -  History or presence of sustained ventricular arrhythmias or atrial fibrillation&#xD;
&#xD;
          -  Clinically significant resting bradycardia (&lt; 50 beats per minutes) QTc &gt; 480 msec on&#xD;
             screening ECG&#xD;
&#xD;
          -  Complete left bundle branch block&#xD;
&#xD;
          -  Right bundle branch block + left anterior hemiblock (bifascicular block)&#xD;
&#xD;
          -  Unstable angina pectoris ≤ 6 months prior to starting study drug&#xD;
&#xD;
          -  Acute myocardial infarction ≤ 6 months prior to starting study drug&#xD;
&#xD;
          -  Other clinically significant heart disease such as congestive heart failure requiring&#xD;
             treatment (NYHA Class III or IV) or uncontrolled hypertension (please refer to WHO-ISH&#xD;
             guidelines)&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,&#xD;
             active or uncontrolled infection) that could cause unacceptable safety risks or&#xD;
             compromise compliance with the protocol&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection). Patients with&#xD;
             unresolved diarrhea will be excluded as previously indicated&#xD;
&#xD;
          -  Patients who have been treated with any hematopoietic colony-stimulating growth&#xD;
             factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin&#xD;
             or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be&#xD;
             continued&#xD;
&#xD;
          -  Patients who are currently receiving treatment with QT prolonging medication with a&#xD;
             known risk to induce Torsades de Pointes and the treatment cannot either be&#xD;
             discontinued or switched to a different medication prior to starting study drug.&#xD;
             Please refer to Appendix E for a list of prohibited drugs.&#xD;
&#xD;
          -  Patient is currently being treated with drugs known to be moderate and strong&#xD;
             inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or&#xD;
             switched to a different medication prior to starting study drug. Please refer to&#xD;
             Appendix B for a list of prohibited CYP 3A4 inhibitors and inducers.&#xD;
&#xD;
          -  Patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study&#xD;
             drug. Systemic corticosteroids should not be administered with BKM120 (Usage of&#xD;
             steroids as premedications and anti-emetics for paclitaxel and carboplatin, per MSKCC&#xD;
             guidelines, is allowed). Steroids given as part of pre-medications for imaging studies&#xD;
             are not exclusionary.).&#xD;
&#xD;
          -  Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6&#xD;
             weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who&#xD;
             have not recovered from side effects of such therapy (except alopecia)&#xD;
&#xD;
          -  Patients who have received any continuous or intermittent small molecule therapeutics&#xD;
             (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study&#xD;
             drug or who have not recovered from side effects of such therapy (except alopecia)&#xD;
&#xD;
          -  Patients who have received radiotherapy within ≤ 4 weeks prior to registration&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who are currently taking therapeutic doses of warfarin sodium or any other&#xD;
             coumadin-derivative anticoagulant.&#xD;
&#xD;
          -  Patient is currently being treated with olanzapine and/or other drugs known to be&#xD;
             moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment&#xD;
             cannot be discontinued or switched to a different medication prior to starting study&#xD;
             drug.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding or adults of reproductive potential not&#xD;
             employing an effective method of birth control. Double barrier contraceptives must be&#xD;
             used through the trial by both sexes. Oral, implantable, or injectable contraceptives&#xD;
             may be affected by cytochrome P450 interactions, and are therefore not considered&#xD;
             effective for this study.&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  History of another malignancy within 3 years, except cured basal cell carcinoma of the&#xD;
             skin or excised carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patient is unable or unwilling to abide by the study protocol or cooperate fully with&#xD;
             the investigator&#xD;
&#xD;
          -  More than 2 prior cytotoxic chemotherapy regimens for recurrent or metastatic disease&#xD;
&#xD;
          -  Patients with multifocal peripheral sensory alterations or paresthesias (including&#xD;
             tingling) interfering with function, per patient report (example: activities of daily&#xD;
             living).&#xD;
&#xD;
          -  Patients receiving other investigational therapies&#xD;
&#xD;
          -  Patients receiving herbal preparations/medications&#xD;
&#xD;
          -  Patients with any prior history of whole pelvic radiation therapy (WPRT)&#xD;
&#xD;
          -  EXPANSION COHORT A ONLY: More than one prior cytotoxic chemotherapy regimen (in the&#xD;
             setting of recurrent and/or metastatic disease (cytotoxic chemotherapy given as part&#xD;
             of neo-adjuvant therapy, adjuvant therapy, or concurrent chemoradiation for curative&#xD;
             intent is not included in this exclusion item). This does not apply to Expansion&#xD;
             Cohort B.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hyman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BKM120</keyword>
  <keyword>CARBOPLATIN</keyword>
  <keyword>TAXOL (PACLITAXEL)</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>10-192</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

